Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial

详细信息    查看全文

• 作者：Kenichi Tanaka ; Masaaki Nakayama ; Makoto Kanno…
• 关键词：Chronic kidney disease (CKD) ; Febuxostat ; Hyperuricemia ; Urinary albumin ; Urinary beta 2 microglobulin (尾2MG) ; Urinary liver ; type fatty acid ; binding protein (L ; FABP)
• 刊名：Clinical and Experimental Nephrology
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：19
• 期：6
• 页码：1044-1053
• 全文大小：653 KB
• 参考文献：1.Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999;56(6):2214鈥?. doi:10.鈥?046/鈥媕.鈥?523-1755.鈥?999.鈥?0773.鈥媥 .CrossRef PubMed
  2.Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(12 Suppl):S16鈥?3.PubMed
  3.Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296鈥?05. doi:10.鈥?056/鈥婲EJMoa041031 .CrossRef PubMed
  4.Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154鈥?9. doi:10.鈥?161/鈥?1.鈥婥IR.鈥?000095676.鈥?0936.鈥?0 .CrossRef PubMed
  5.Nakayama M, Metoki H, Terawaki H, Ohkubo T, Kikuya M, Sato T, et al. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population鈥搕he Ohasama study. Nephrol Dial Transplant. 2007;22(7):1910鈥?. doi:10.鈥?093/鈥媙dt/鈥媑fm051 .CrossRef PubMed
  6.Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44(4):642鈥?0 [pii:S0272638604009345].CrossRef PubMed
  7.Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007;50(2):239鈥?7. doi:10.鈥?053/鈥媕.鈥媋jkd.鈥?007.鈥?5.鈥?13 .CrossRef PubMed
  8.Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS. Uric acid and incident kidney disease in the community. J Am Soc Nephrol. 2008;19(6):1204鈥?1. doi:10.鈥?681/鈥婣SN.鈥?007101075 .PubMedCentral CrossRef PubMed
  9.Kamei K, Konta T, Hirayama A, Suzuki K, Ichikawa K, Fujimoto S, et al. A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population. Nephrol Dial Transplant. 2014;. doi:10.鈥?093/鈥媙dt/鈥媑fu256 .
  10.Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53(5):796鈥?03. doi:10.鈥?053/鈥媕.鈥媋jkd.鈥?008.鈥?2.鈥?21 .PubMedCentral CrossRef PubMed
  11.Suliman ME, Johnson RJ, Garcia-Lopez E, Qureshi AR, Molinaei H, Carrero JJ, et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis. 2006;48(5):761鈥?1. doi:10.鈥?053/鈥媕.鈥媋jkd.鈥?006.鈥?8.鈥?19 .CrossRef PubMed
  12.Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811鈥?1. doi:10.鈥?056/鈥婲EJMra0800885 .PubMedCentral CrossRef PubMed
  13.Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41(6):1183鈥?0. doi:10.鈥?161/鈥?1.鈥婬YP.鈥?000069700.鈥?2727.鈥婥5 .CrossRef PubMed
  14.Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388鈥?3. doi:10.鈥?215/鈥婥JN.鈥?1580210 .PubMedCentral CrossRef PubMed
  15.Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76(1):47鈥?6. doi:10.鈥?016/鈥?002-9343(84)90743-5 .CrossRef PubMed
  16.Omori H, Kawada N, Inoue K, Ueda Y, Yamamoto R, Matsui I, et al. Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. Clin Exp Nephrol. 2012;16(4):549鈥?6. doi:10.鈥?007/鈥媠10157-012-0609-3 .CrossRef PubMed
  17.Sezai A, Soma M, Nakata K, Hata M, Yoshitake I, Wakui S, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). Circ J. 2013;77(8):2043鈥?. doi:10.鈥?253/鈥媍ircj.鈥婥J-13-0082 .CrossRef PubMed
  18.Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982鈥?2. doi:10.鈥?053/鈥媕.鈥媋jkd.鈥?008.鈥?2.鈥?34 .CrossRef PubMed
  19.Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63. doi:10.鈥?186/鈥媋r2978 .PubMedCentral CrossRef PubMed
  20.Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis. 2010;56(2):264鈥?2. doi:10.鈥?053/鈥媕.鈥媋jkd.鈥?010.鈥?1.鈥?19 .CrossRef PubMed
  21.Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47(1):51鈥?. doi:10.鈥?053/鈥媕.鈥媋jkd.鈥?005.鈥?0.鈥?06 .CrossRef PubMed
  22.Whelton A, MacDonald PA, Chefo S, Gunawardhana L. Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med. 2013;125(1):106鈥?4. doi:10.鈥?810/鈥媝gm.鈥?013.鈥?1.鈥?626 .CrossRef PubMed
  23.Tsuda H, Kawada N, Kaimori JY, Kitamura H, Moriyama T, Rakugi H, et al. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. Biochem Biophys Res Commun. 2012;427(2):266鈥?2. doi:10.鈥?016/鈥媕.鈥媌brc.鈥?012.鈥?9.鈥?32 .CrossRef PubMed
  24.Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924鈥?2. doi:10.鈥?001/鈥媕ama.鈥?00.鈥?.鈥?24 .PubMedCentral CrossRef PubMed
  25.Agarwal V, Messerli F. Effect of allopurinol on blood pressure (author response to Allopurinol on hypertension: insufficient evidence to recommend). J Clin Hypertens (Greenwich). 2013;15(9):701. doi:10.鈥?111/鈥媕ch.鈥?2152 .CrossRef
  26.Shibagaki Y, Ohno I, Hosoya T, Kimura K. Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. Hypertens Res. 2014;37(10):919鈥?5. doi:10.鈥?038/鈥媓r.鈥?014.鈥?07 .CrossRef PubMed
  27.Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101鈥?.CrossRef PubMed
  28.Kobrin I, Frohlich ED, Ventura HO, Messerli FH. Renal involvement follows cardiac enlargement in essential hypertension. Arch Intern Med. 1986;146(2):272鈥?.CrossRef PubMed
  29.Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67(5):1739鈥?2. doi:10.鈥?111/鈥媕.鈥?523-1755.鈥?005.鈥?0273.鈥媥 .CrossRef PubMed
  30.Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26(2):269鈥?5. doi:10.鈥?097/鈥婬JH.鈥?b013e3282f240bf鈥?/span> .CrossRef PubMed
  31.Povoa H Jr, Sa LD, Lessa VM. Xanthine oxidase and triglycerides in serum of patients with hyperlipoproteinemia, type IV. Biomed Biochim Acta. 1984;43(10):1201鈥?.PubMed
  32.Sanchez-Lozada LG, Tapia E, Bautista-Garcia P, Soto V, Avila-Casado C, Vega-Campos IP, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2008;294(4):F710鈥?. doi:10.鈥?152/鈥媋jprenal.鈥?0454.鈥?007 .CrossRef PubMed
  33.Real JT, Martinez-Hervas S, Garcia-Garcia AB, Civera M, Pallardo FV, Ascaso JF, et al. Circulating mononuclear cells nuclear factor-kappa B activity, plasma xanthine oxidase, and low grade inflammatory markers in adult patients with familial hypercholesterolaemia. Eur J Clin Invest. 2010;40(2):89鈥?4. doi:10.鈥?111/鈥媕.鈥?365-2362.鈥?009.鈥?2218.鈥媥 .CrossRef PubMed
  34.Saviola G, Benucci M, Abdi-Ali L, Sacco S, Cera I, Rossini M. Can febuxostat reduce triglyceride and cholesterol serum levels in gouty patients? J Clin Rheumatol. 2014;20(7):394鈥?. doi:10.鈥?097/鈥婻HU.鈥?000000000000168鈥?/span> .PubMed
  35.Hosoya T, Kimura K, Itoh S, Inaba M, Uchida S, Tomino Y, et al. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. Trials. 2014;15:26. doi:10.鈥?186/鈥?745-6215-15-26 .PubMedCentral CrossRef PubMed
  
• 作者单位：Kenichi Tanaka (1)
  Masaaki Nakayama (1)
  Makoto Kanno (1)
  Hiroshi Kimura (1)
  Kimio Watanabe (1)
  Yoshihiro Tani (1)
  Yoshimitsu Hayashi (1)
  Koichi Asahi (1)
  Hiroyuki Terawaki (1)
  Tsuyoshi Watanabe (1)
  
  1. Department of Nephrology and Hypertension, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Nephrology
  Internal Medicine
  Urology and Andrology
  
• 出版者：Springer Japan
• ISSN：1437-7799

文摘

Background Hyperuricemia is associated with the onset of chronic kidney disease (CKD) and renal disease progression. Febuxostat, a novel, non-purine, selective xanthine oxidase inhibitor, has been reported to have a stronger effect on hyperuricemia than conventional therapy with allopurinol. However, few data are available regarding the clinical effect of febuxostat in patients with CKD.